Interventional and Surgical Modalities of Treatment in Pulmonary Hypertension  by Keogh, Anne M. et al.
C
c
(
w
u
i
m
m
p
p
a
a
n
t
t
F
M
H
U
¶
S
A
t
t
Journal of the American College of Cardiology Vol. 54, No. 1, Suppl S, 2009
© 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00
PInterventional and Surgical Modalities
of Treatment in Pulmonary Hypertension
Anne M. Keogh, MBBS, PHD,* Eckhard Mayer, MD,† Raymond L. Benza, MD,‡ Paul Corris, MD,§
Philippe G. Dartevelle, MD, Adaani E. Frost, MD,¶ Nick H. Kim, MD,# Irene M. Lang, MD,**
Joanna Pepke-Zaba, PHD,†† Julio Sandoval, MD‡‡
Sydney, Australia; Mainz, Germany; Pittsburgh, Pennsylvania; Newcastle upon Tyne and Cambridge,
United Kingdom; Le Plessis Robinson, France; Houston, Texas; La Jolla, California; Vienna, Austria;
and Mexico City, Mexico
Most patients with chronic thromboembolic pulmonary hypertension are operable, and pulmonary endarterec-
tomy is the treatment of choice. Pulmonary endarterectomy should not be delayed for medical therapy, and risk
stratification helps to define patients likely to achieve the best outcome. Inoperable patients should be referred
for trials of medical agents. Atrial septostomy is promising but underutilized, although better ways of ensuring
an adequate, lasting septostomy still need to be determined. Indications for the procedure are unchanged, and
it should be considered more frequently. Bilateral sequential lung or heart–lung transplantation is an important
option for selected patients, and potential candidates who are class IV or III but not improving should be referred
early to a transplantation center. Currently, there is a need for right ventricular assist devices with flow charac-
teristics suited to the circulation of patients with pulmonary arterial hypertension. Right ventricular synchroniza-
tion therapy has not yet been tested. Novel shunts (e.g., Potts anastomosis) also hold promise. All surgery for
pulmonary hypertension should be performed in centers with experience in these techniques. (J Am Coll
Cardiol 2009;54:S67–77) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.04.016D
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vhronic thromboembolic pulmonary hypertension (CTEPH)
an be defined as pulmonary arterial hypertension (PAH)
mean pulmonary arterial pressure [mPAP] 25 mm Hg)
ith persistent pulmonary perfusion defects. CTEPH is an
nderdiagnosed cause of PAH and carries a poor prognosis
f untreated (1–3). Acute or recurrent pulmonary emboli
ay be the initiating event. These are followed by intralu-
inal thrombus organization, fibrous obstruction of affected
roximal arteries, and vascular remodeling in patent distal
ulmonary arteries (4,5). CTEPH, therefore, is a disease with
mechanical component potentially amenable to surgery,
nd a variable degree of small vessel arteriopathy. Pulmo-
ary endarterectomy (PEA) is a potential cure, and the
reatment of choice for CTEPH (6,7); therefore, differen-
iation between CTEPH and PAH is paramount.
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ince the 3rd World Symposium on Pulmonary Hypertension
eld in Venice in 2003 (8), the diagnostic algorithm for
TEPH has not significantly changed. The main diagnostic
lue is the presence of 1 or more persistent perfusion defects on
entilation–perfusion scanning. Hemodynamic measurements
id in predicting prognosis and perioperative risk assessment.
ultiplanar pulmonary angiography is the gold standard for
he confirmation of chronic thromboembolic disease and is
ecommended for the assessment of operability (6). Multislice
omputed tomographic scanning (Fig. 1) and magnetic reso-
ance imaging have become valuable complementary investi-
ations (3,9,10). Maximum information regarding pulmonary
rterial morphology is required to assess surgical risk and
ong-term outcome; this information can best be obtained with
ulmonary angiography. Patients should be referred for eval-
ation by a multidisciplinary team experienced in PEA.
There is inadequate evidence that PAH-specific medical
herapy is an alternative to surgery (11), and the operation
hould not be delayed in favor of medical therapy. The best
utcomes after surgery are associated with surgeon and center
xperience; concordance between pre-operative pulmonary
ascular resistance (PVR) and anatomic disease; pre-operative
VR1,000 to 1,200 dynes/s/cm5; absence of select comor-
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Interventional and Surgical Modalities of Treatment June 30, 2009:S67–77bidities, such as splenectomy or
ventriculoatrial shunt; and signifi-
cant post-operative decrease in
PVR (7,12–14).
Surgery does not benefit all
CTEPH patients (3). In high-
risk patients with a likelihood of
having significant distal small
vessel disease pre-operatively and
limited proximal angiographic
pulmonary artery obstruction, a
trial of PAH-specific medical
therapy may be a reasonable op-
tion (3,11). However, the role of
medical therapy in CTEPH re-
mains to be further tested and
defined.
Currently there is no pre-
operative classification system that
might allow for better risk stratifi-
cation (15). In conjunction with
PVR, exploratory variables such as
pre-operative diffusion capacity,
upstream resistance, select bio-
markers, and precise assessment
of right ventricular (RV) dysfunc-
tion may have a role in a future
classification system (16–21).
The San Diego surgical classi-
fication (22) is based on operative
findings of pulmonary artery ob-
struction, and therefore is not
suitable for pre-operative risk
stratification. Currently, the rec-
ommendation for surgery is
based on a careful analysis by an
experienced multidisciplinary
team.
PEA
The PEA procedure with deep
hypothermic circulatory arrest
(DHCA) to ensure a bloodless
field while providing cerebral
rotection has been described elsewhere (7,13). Optimal
ntraoperative visibility of pulmonary artery branches is the
rerequisite for complete endarterectomy and maximal RV
fterload reduction. The best operative outcome is depen-
ent on a complete endarterectomy and significant early
eduction of PVR to 500 dynes/s/cm5 (13). Different
echniques for minimizing risk of circulatory arrest have
een published (23,24); however, the mortality rates seem
orse compared with larger series that included DHCA.
pecialists at the University of California, San Diego,
Abbreviations
and Acronyms
AS  atrial septostomy
BLTx  bilateral lung
transplantation
CI  cardiac index
CO  cardiac output
CTEPH  chronic
thromboembolic pulmonary
hypertension
DHCA  deep hypothermic
circulatory arrest
ECLS  extracorporeal life
support
ECMO  extracorporeal
membrane oxygenation
HLTx  heart–lung
transplantation
IPAH  idiopathic
pulmonary arterial
hypertension
IVC  inferior vena cava
LV  left ventricle/
ventricular
mPAP  mean pulmonary
arterial pressure
mRAP  mean right atrial
pressure
NYHA  New York Heart
Association
PAH  pulmonary arterial
hypertension
PEA  pulmonary
endarterectomy
PH  pulmonary
hypertension
PVR  pulmonary vascular
resistance
RAP  right atrial pressure
RV  right ventricular
6MWD  six-min walk
distance
SOT  systemic arterial
oxygen saturationeported a 4.4% mortality and 0% neurological morbidity in e00 consecutive PEA operations using DHCA (13). At
resent, there is no compelling rationale for changing the
EA techniques used by major centers around the world.
ost-operative management. Right heart dysfunction
aused by residual pulmonary hypertension (PH) and pul-
onary vasoconstriction after extracorporeal circulation,
nd reperfusion edema in endarterectomized segments of
he lung can pose significant challenges after PEA (7,25).
owever, optimal post-operative care has not been defined,
nd treatment protocols vary among expert centers.
In most patients, RV afterload reduction by removal of
bstructive material from the pulmonary vasculature will
esult in an immediate and significant decrease of pulmo-
ary artery pressures, increase in cardiac index (CI), im-
roved gas exchange, and diuresis. Medical treatment in-
ludes cautious fluid administration, maintaining low right
trial pressure (RAP), and administration of vasoconstric-
ive drugs, if systemic hypotension caused by vasodilatation
s present. Reduction of the CI to pre-operative levels may
e necessary to minimize flooding of the lungs (reperfusion
dema). Although the achievement of adequate gas ex-
hange is a basic tenet of post-operative care after PEA, and
ulmonary reperfusion response can be a serious problem,
here is no consensus with respect to ventilatory protocols,
ven in specialized centers. It is uncertain whether mechan-
cal ventilation with high tidal volumes and a limited degree
f positive end-expiratory pressure, or nonaggressive
ressure-controlled ventilation with high positive end-
xpiratory pressure, provides better results with regard to gas
Figure 1 CT Scan of a Patient With Chronic
Thromboembolic Pulmonary Hypertension
Computed tomographic (CT) scan depicting occlusions of right lobar and seg-
mental pulmonary artery branches without proximal disease of the left pulmo-
nary artery (64-slice CT, 3-dimensional reconstruction of volumetric data set
with retrospective electrocardiographic gating). Courtesy of Christopher Ahlers,
MD, Department of Radiology, Johannes Gutenberg University Hospital, Mainz,
Germany.xchange and hemodynamic effects. Nevertheless, early
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June 30, 2009:S67–77 Interventional and Surgical Modalities of Treatmentxtubation 1 or 2 days post-surgery is possible with both
rotocols in a majority of patients (26).
In a small number of patients, post-operative right heart
ailure develops because of severe persistent PH caused by
ncomplete endarterectomy or small vessel disease combined
ith the effects of extracorporeal circulation, hypothermia,
nd ischemia (26). Attempts should be made to optimize
ight heart function with inotropic agents and reduce RV
fterload. The role of treatment with specific pulmonary
asodilators in this challenging situation is unclear, although
here is limited information that inhaled iloprost might be
seful (11,27).
Early reocclusion prophylaxis using intravenous or sub-
utaneous heparin and subsequent lifelong anticoagulation
s mandatory for all post-PEA patients. The routine pre-
perative insertion of an inferior vena cava (IVC) filter to
educe the risk of peri-operative or recurrent pulmonary
mbolism remains a matter of debate. A randomized trial to
ompare optimal surveillance anticoagulation with or with-
ut IVC filter is warranted.
utcome. The concept of PEA has been transferred from
he University of California, San Diego, to an increasing
umber of centers internationally. A recent report from San
iego included a cohort of 1,100 patients with post-PEA
ortality rates of 4.7% (28). With increasing experience, PEA
enters should strive for post-operative mortality rates 10%.
ince results depend on experience with the procedure, the
umber of centers per region may have to be limited.
Although the outcome of PEA in patients with CTEPH
as not been evaluated in randomized controlled studies,
ong-term results with respect to survival, functional status,
xercise capacity, quality of life, RV function, hemodynam-
cs, and gas exchange are favorable for most patients
7,13,29–31). Maximum benefits of surgery may take 6
onths or more. To exclude recurrent disease or residual
ymptomatic PH, patients should be systematically followed
p with hemodynamic re-evaluation 6 to 12 months after
urgery. In cases of residual or recurrent PH, specific
ulmonary vasodilatory treatment might be beneficial
11,27,32), although further randomized controlled studies
re needed.
onsensus
CTEPH is defined as symptomatic PAH (mPAP 25
mm Hg) with persistent perfusion defects.
CTEPH has a mechanical component judged amenable
to surgery as well as variable small vessel disease.
Pulmonary endarterectomy is the treatment of choice for
CTEPH.
Once CTEPH is diagnosed, patients should be referred
for surgical evaluation by an experienced multidisci-
plinary team.
In candidates found to be operable:
X pulmonary endarterectomy is efficacious and carries aclear survival benefit; (X there is inadequate evidence that medical therapy
(PAH-specific therapy) is an alternative to surgery;
X surgery should not be delayed in favor of medical
therapy;
X current best practice results in operative mortality
rates of 4% to 7%.
Pre-operative risk stratification requires better definition.
The best outcomes at present are associated with:
X surgeon and center experience;
X concordance between PVR and anatomic disease;
X pre-operative PVR 1,000 to 1,200 dynes/s/cm5;
X absence of select comorbidities (e.g., splenectomy,
ventriculoatrial shunts);
X post-operative PVR 500 dynes/cm/s5.
Benefits of surgery may not be immediate: full benefits
may take 6 months.
Patients should be systematically followed up with he-
modynamic re-evaluation at 6 to 12 months after surgery
because response may be partial or disease may recur.
It is unknown whether the current PAH-specific medi-
cations are effective in post-operative persistent PH;
studies are required.
In CTEPH patients judged to be inoperable, a ran-
domized, placebo-controlled, double-blind trial with
bosentan showed modest improvement in hemody-
namics but no change in 6-min walk distance at short
follow-up (33).
No consensus could be reached regarding the role of IVC
filters in CTEPH candidates.
ecommendations
Pre-operative risk stratification requires further develop-
ment. Variables other than PVR (pre-operative diffusion
capacity, pulmonary artery occlusion technique, emerging
biomarkers, precise assessment of RV dysfunction) may
have a role.
The collaboration of major centers with experience in
PEA is recommended to pool data prospectively for
comprehensive analysis of risk factors and best-practice
guidelines.
A pre-operative classification system should be developed
for future use.
A randomized trial of optimal surveillance anticoagula-
tion with or without an IVC filter is warranted.
The role of medical therapy in patients deemed to be
inoperable needs to be further tested and defined.
trial Septostomy (AS) in Severe PAH
ationale. In advanced idiopathic pulmonary arterial hy-
ertension (IPAH), either normal RV function or compen-
ated hypertrophy is critical for survival (34). Patients with
isenmenger syndrome have better survival rates than
atients with IPAH (35,36) and the concept that AS
uccessfully decompresses the failing RV and left ventricle
LV) is well accepted. Atrial septostomy represents a strat-
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Interventional and Surgical Modalities of Treatment June 30, 2009:S67–77gy for the treatment of RV failure where medical therapy is
ailing and there is limited access to lung donors. It allows
ight-to-left shunting, as permitted by the presence of
ricuspid regurgitation, and increased systemic output,
hich allows increased systemic oxygen transport, in spite of
decrease in systemic arterial oxygen saturation (SOT)
37,38).
lobal experience. Based on the worldwide literature, we
resented an updated analysis at the Dana Point meeting
omprising 223 cases, including children, with a mean age
f 28  17 years. Seventy percent of patients were female,
2% had IPAH, and mean New York Heart Association
NYHA) functional class was 3.6  0.4 (J. Sandoval,
npublished written communication, February 2008).
ther etiologies were PAH associated with surgically cor-
ected congenital heart disease (8%), collagen vascular dis-
ase (5%), distal CTEPH not amenable to surgery (3%),
nd miscellaneous (3%). Congestive heart failure (43%),
yncope (38%), or both (19%) were the principal indications
or the procedure, with bridge to transplantation in 14% of
ases. Of patients who underwent AS, 96 were nonrespon-
ive to maximal medical treatment, including intravenous
rostacyclin infusion (n 57), bosentan (n 18), sildenafil
n  8), beraprost (n  6), subcutaneous treprostinil (n 
), inhaled iloprost (n  3), or combination therapy (n 
0). The simultaneous use of pharmacologic therapy and
S in these reports, as well as the evidence for the safe
dministration of intravenous epoprostenol, subcutaneous
reprostinil, or bosentan in the setting of PAH associated
ith Eisenmenger syndrome (39–41), support the safety of
combination of medical and surgical treatment.
rocedures. Two techniques have been used. Stepwise
alloon dilatation is the procedure of choice. In stepwise
alloon-dilation AS, the interatrial orifice is created by
uncture with a Brockenbrough needle, then dilated using
rogressively larger balloon catheters. A 10% decrease in
rterial oxygen saturation (SaO2%) and an increase in LV
nd-diastolic pressure to 18 mm Hg preclude further
ecommendations for Minimizingrocedur -Related Mortality of Atrial Septostomy
Table 1 Recommendations for MinimizingProcedure-Related Mortality of Atrial Septostomy
1. Only perform in a center experienced in pulmonary hypertension.
2. Contraindications to AS (unchanged from 2003) are severe right ventricular
failure on cardiorespiratory support, mRAP 20 mm Hg, PVRI 55 U/m2,
resting O2 saturation 90% on room air, and LVEDP 18 mm Hg.
3. Pre-procedure, optimize cardiac function with adequate right heart filling
pressure and additional inotropic support if needed.
4. During procedure:
a. Supplemental oxygen
b. Appropriate sedation to prevent anxiety
c. Monitoring variables (LAP, SaO2%, and mRAP)
d. Tailor the defect to 10% decrease in O2 saturation.
5. Post-procedure, optimize oxygen delivery with transfusion of packed red blood
cells or darbepoetin before and after.
S atrial septostomy; LAP left atrial pressure; LVEDP left ventricular end diastolic pressure;N
RAPmean right atrial pressure; PVRI pulmonary vascular resistance index; SaO2% arterial
xygen saturation.ilatation (42). No prospective hemodynamic evaluation has
een performed. There are no guidelines for the optimal size
f the defect. Anecdotally, a defect size of 8.5  2 mm is
aid to increase cardiac output (CO) by 20% to 25%. The
efect may close and require a repeat procedure.
The choice between balloon-dilation AS or blade balloon
S depends on center expertise and should include both
nterventional cardiology and PH expertise. Alternative
echniques with a custom-made fenestrated Amplatzer
AGA Medical, Golden Valley, Minnesota) device or a
utterfly stent at the end of the procedure to keep the AS
atent have met with modest success (43,44).
mmediate outcome after AS. In most reports, AS was
erformed in severe PAH with RV failure with an overall
rocedure-related mortality of 16% (45). Recommendations
o minimize risk have been established (Table 1). In our
nalysis of 223 cases, mortality was 7.1% at 24 h and 14.8%
t 1 month. Factors significantly associated with procedure-
elated mortality at 1 month are shown in Table 2. The
ost common cause of death within 24 h was refractory
ypoxemia. Less common were progressive right heart
ailure, procedural complications, multiple organ failure,
emoptysis, and withdrawal of dialysis. From a total of 186
eported surviving patients with early follow-up, syncope
nd right heart failure improved in 88%, and 12% were
nimproved. In all, 16.6% were transplanted. The 6-min
alk distance (6MWD) improved 30% to 100% (46–48).
mmediate hemodynamic response. In our updated anal-
sis of 223 cases, hemodynamic results before and after AS
ere reported in 117 patients. There was a significant
ecrease in mRAP (14.6  8 mm Hg to 11.6  6.3 mm
g; p  0.0001), SaO2% (93.3  4.1% to 83  8.5%), and
ariables Associated With-Month Mortality, Univariate Analysis
Table 2 Variables Associated With1-Month Mortality, Univariate Analysis
Variable
Hazard Ratio
(95% Confidence Interval) p Value
RAP 20 mm Hg 30.5 (3.8–244) 0.001*
NYHA functional class 8.53 (0.89–81.2) 0.062*
RHF 5.97 (0.75–47.2) 0.089
Mean RAP, mm Hg 1.19 (1.1–1.29) 0.0001*
Septostomy type, blade 1.19 (0.30–4.6) 0.800
Age 18 yrs 1.12 (0.29–4.34) 0.865
Mean LAP, mm Hg 1.11 (0.86–1.43) 0.420
Baseline PVRI, U/m2 1.04 (0.98–1.09) 0.148
Mean PAP, mm Hg 1.01 (0.98–1.05) 0.321
Age, yrs 0.99 (0.96–1.03) 0.966
Baseline SaO2% 0.97 (0.83–1.14) 0.773
Mean SAP, mm Hg 0.96 (0.92–1.01) 0.148
SaO2% after procedure 0.90 (0.84–0.96) 0.001*
Gender, female 0.73 (0.18–2.8) 0.635
Baseline CI, l/min/m2 0.38 (0.09–1.6) 0.189
Syncope 0.14 (0.03–0.66) 0.013*
p values are statistically significant.
CI  cardiac index; NYHA  New York Heart Association; PAP  pulmonary arterial pressure;
AP  right atrial pressure; RHF  right heart failure; SAP  systemic arterial pressure; other
bbreviations as in Table 1.YHA functional class (3.49  0.6 to 2.1  0.7), accom-
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m Hg to 8.1  4.0 mm Hg; p  0.0001) and CI (2.04 
.69 l/min/m2 to 2.62  0.84 l/min/m2).
Hemodynamic improvement is contingent on baseline
RAP (42,45,49) (Table 3). In patients with an mRAP
10 mm Hg, the decrease in mRAP was not significant
–10.6% from an already-low baseline reading), yet there
as a 22.5% increase in CI. In patients with an mRAP20
m Hg (in whom procedural mortality is highest), mRAP
nd SaO2% decreased 25% and 15%, respectively, and CI
ncreased 38% from baseline. Patients with a baseline
RAP between 11 and 20 mm Hg had an intermediate
esponse but a better risk/benefit ratio (47). These measure-
ents represent only the resting state and are likely to be
ifferent with exercise, explaining the increase in 6MWD
46–48). Post-AS hemodynamics during exercise have not
een established.
An increase in PVR, low mixed venous PO2, and refrac-
ory hypoxemia after AS have been successfully managed
ith inhaled iloprost (50). The increase in CO with no
hange in PAP or PVR suggests that the mechanism may be
V decompression and improved LV filling. Clinical im-
rovement occurs despite resting desaturation and further
esaturation with exercise.
Mechanisms for hemodynamic and clinical benefit in-
lude decompression of the RV at rest, prevention of further
V dilation and dysfunction during exercise, and an in-
rease in CO and SOT, both at rest and during exercise (via
ight-to-left shunt). The increase in SOT and delivery also
roduces beneficial effects on peripheral oxygen utilization
nd decreased muscle sympathetic nerve activity (42,51–53).
ong-term hemodynamics and survival. Evaluation of
ong-term hemodynamics showed a higher CI and lower
AP in patients at repeat catheterization after a mean of 2
ears post-septostomy (36). Echocardiography at 5.5
onths after AS showed a significant decrease in right atrial
nd RV systolic and diastolic areas (54).
Of the 223 cases presented at Dana Point, follow-up
nformation was available for 128. For these 128 patients,
edian survival was 60 months and mean survival time was
2.3 months. The mean survival after AS (excluding proce-
ural deaths) was 63.1 months. Mortality after septostomy
emodynamic Effects of Atrial Septostomy Related to Baseline Re
Table 3 Hemodynamic Effects of Atrial Septostomy Related to
Variable
mRAP <10 mm Hg (n  42) m
Before After p Value Befo
mRAP, mm Hg 6.6 2.4 5.9 3.2 0.214 14.8
mPAP, mm Hg 62 16 64 19 0.329 66.4
mLAP, mm Hg 5.0 2.7 6.8 2.4 0.005 5.3
SaO2% 93.8 4 85.8 7 0.0001 93.0
CI, l/min/m2 2.36 0.6 2.89 0.7 0.0001 2.04
mSAP, mm Hg 83 15 83 13 0.931 84.5
NYHA functional class 3.25 0.6 2.00 0.7 0.0001 3.63
LAP  mean left atrial pressure; mPAP  mean pulmonary arterial pressure; mSAP  mean syexcluding procedure-related mortality) was dictated by older •ge (hazard ratio [HR]: 1.04), scleroderma (HR: 8.32),
YHA functional class (HR: 4.71), NYHA class III and IV
HR: 6.24), CI (HR: 0.179), left atrial pressure (HR: 0.737),
nd SOT (HR: 0.99). The impact of baseline mRAP on
urvival, which is relevant before septostomy, disappears once
he procedure has been performed. A diagnosis of scleroderma
egatively impacts survival after AS.
Post-septostomy survival of patients with severe PH and
ight heart failure seems at least comparable to that achiev-
ble with current pharmacologic agents. However, given
hat a significant proportion of patients were receiving
edications before and after the procedure, it is difficult to
eparate the relative benefits.
ummary. Atrial septostomy stands as an additional prom-
sing strategy in the treatment of severe PAH. It can be
erformed successfully in selected patients with advanced
ulmonary vascular disease. In patients with PAH who have
ndergone successful AS, the procedure has resulted in a
ignificant clinical improvement, beneficial and long-lasting
emodynamic effects at rest, and a trend toward improved
urvival. Procedure-related mortality is still high but seems
o be decreasing since recommendations to minimize risk
ere implemented. However, because the disease process in
AH is unaffected, AS is considered a palliative procedure.
Indications for AS include: 1) failure of maximal medical
herapy, persisting RV failure, and/or recurrent syncope; 2) as
bridge to transplantation; and 3) when no other therapeutic
ptions exist (8,55).
onsensus
The concept that AS decompresses the RV is accepted.
Uptake has been limited. Impediments may be lack of a
training pathway or the terminology “palliative procedure.”
Patients known to benefit from AS have IPAH with
syncope or persistent RV failure or have received failed
medical therapy.
Atrial septostomy has a role in health care systems
without drug access.
Atrial septostomy has been used to bridge to lung
transplantation and might prolong survival for patients
on a waiting list.
Mean Right Atrial Pressure
line Resting Mean Right Atrial Pressure
11–20 mm Hg (n  49) mRAP >20 mm Hg (n  26)
After p Value Before After p Value
11.9 3.5 0.0001 26.6 4.4 19.9 3.8 0.0001
66.4 16 1.000 63.4 20 67.5 20 0.102
7.8 4.5 0.0001 7.9 3.0 10.9 4.0 0.029
82.8 7.2 0.0001 93.1 4.3 78.6 10.3 0.0001
2.65 1.0 0.0001 1.55 0.5 2.14 0.6 0.0001
88.8 15 0.065 78 20 81 18 0.254
2.21 0.8 0.0001 3.71 0.5 2.00 0.0 0.0001
arterial pressure; other abbreviations as in Tables 1 and 2.sting
Base
RAP
re
2.8
17
3.6
4.0
0.7
14
0.5Stepwise balloon dilatation is the procedure of choice.
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tomy, butterfly stents, and cutting-edge balloons.
Selection guidelines are unchanged from 2003: do not
undertake AS if baseline O2 saturation is 90% on room
air or LV end diastolic diameter is 18 mm Hg.
Procedural deaths relate to inadvertent overly large defect
or a decrease in O2 saturation 10%. Deaths are more
common if RAP is 20 mm Hg.
Procedural mortality is approximately 5%.
The defect created should be tailored to the end O2
saturation.
Use in children could be increased.
Spontaneous closure of the defect may require a repeat
procedure.
Survival after AS is superior to survival predicted by the
National Institutes of Health.
The benefit on survival differs from that of single-drug
therapy in that it is immediately apparent.
It is unknown how early in the course of PAH AS may
be useful.
ecommendations
The lack of data on exercise and long-term hemodynam-
ics after AS needs to be addressed.
The role of AS as a bridge to transplantation should be
delineated because it may delay transplantation.
A combination approach of early AS with drug therapy
seems attractive in class IV patients.
A trial of monotherapy patients (stable or deteriorating
class III to IV) randomized to AS or no procedure is
recommended.
ung Transplantation
eart–lung transplantation (HLTx) or bilateral lung trans-
lantation (BLTx) is the final option for selected patients in
hom medical therapy fails (56,57). The most common
ndication is IPAH; less common indications are sclero-
erma, histiocytosis, and sarcoidosis. Use of BLTx and
LTx for PAH has decreased worldwide as the result of
AH-specific medical treatments (58). Nevertheless, pa-
ients in class IV or who remain in class III despite
ombination therapy should be referred for transplantation
ssessment.
atient selection. Published consensus guidelines are used
y major transplantation centers, yet many patients with
PAH are still referred at a late stage, when medical therapy
as failed and multi-organ failure is present. Because the
ack of optimal donor organs is a global problem, death rates
n the waiting list are high for patients with end-stage
AH. Post-operative mortality is significantly higher if
ransplantation is performed in the setting of right heart,
enal, and hepatic failure, and marginal organs may also be
sed. PPotentially eligible class IV patients with IPAH should
e referred immediately for transplantation assessment. The
tiology of PAH, the functional and hemodynamic status,
nd the course of the disease in the particular patient must
e considered to allow optimal timing of the transplantation
isting. Patients with improvements after combination med-
cal therapy over the first 3 months and, in particular, who
ove to class II, can be withdrawn from the waiting list and
losely followed up. In patients remaining in class III on
ombination therapy, transplantation assessment and listing
hould not be delayed.
Patients with pulmonary veno-occlusive disease or pul-
onary capillary hemangiomatosis have the worst prognosis
ecause medical treatment is ineffective (56); these patients
ust be referred for transplantation assessment at the time
f diagnosis. Despite medical treatment, patients with
cleroderma-associated PAH have a worse prognosis than
o patients with IPAH (59), and the transplantation option
hould be discussed earlier. In contrast, patients with
ongenital right-to-left shunts and Eisenmenger syndrome
ave higher survival rates (37,38). Criteria for transplanta-
ion listing for these patients are difficult to define. How-
ver, the decision for transplantation for these patients
hould not be postponed until renal and hepatic failure
ccur, when patients can become unacceptable candidates.
The 6MWD and peak myocardial oxygen consumption
redict survival. Listing algorithms for transplantation in
AH should incorporate hemodynamics because RAP 15
m Hg and a CI 2.0 l/min/m2 are primary determinants
f poor survival (56).
ype of transplantation. In patients with IPAH, BLTx or
LTx are performed in most centers around the world.
ingle-lung transplantation for IPAH has been abandoned
ecause of high rates of pulmonary edema and poor
utcomes.
In patients with congenital cardiac abnormalities and
isenmenger syndrome (particularly atrial septal defect),
solated lung transplantation combined with repair of car-
iac defects is possible. HLTx provides survival advantages
n this group of PAH patients, in whom it should be
onsidered the procedure of choice (60). A HLTx in PAH
s technically easier and preserves airway blood supply. The
edian sternotomy preserves respiratory mechanics, and the
ost-operative course is simpler.
In other etiologies of PAH, the choice between BLTx
nd HLTx remains open, and factors such as organ dona-
ion shortage, local allocation protocols, and center experi-
nce and preference play a role. Patients with PAH requir-
ng 2 or 3 donor organs may be disadvantaged in many
ystems. Because a definite survival benefit for HLTx in
PAH has not been shown, it may not be appropriate to use
he donor organs for 1 recipient rather than 2 if there is no
ajor cardiac disease other than RV dysfunction. There are
everal advantages and disadvantages of BLTx or HLTx,
ut none has proven to be a determinant of survival.
ost-operative RV dysfunction or high blood flow to the
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June 30, 2009:S67–77 Interventional and Surgical Modalities of Treatmentew lungs with an increased LV pre-load can contribute to
rimary graft failure (60). These conditions can be stabilized
y careful post-operative management, and RV function has
een shown to recover following afterload reduction by
ransplantation in IPAH. Airway ischemia is more common
fter isolated lung transplantation compared with HLTx,
ut it was not a significant problem in a recent series of
LTx (57). In HLTx, a shorter ischemic time is mandatory;
his may reduce the possible donor pool. Primary cardiac
raft failure and accelerated long-term coronary artery
isease are drawbacks of HLTx.
utcome. In selected patients with end-stage PAH, the
uality of life, exercise capacity, and long-term survival are
rofoundly improved by lung transplantation. Survival rates
t 3 months after BLTx or combined HLTx for PAH are,
owever, the lowest among all lung transplant recipients
58). Heart–lung recipients with Eisenmenger syndrome
nd IPAH had significantly better overall survival than
atients with other congenital abnormalities. Poor pre-
perative patient status, including multiorgan failure, the
omplexity of the operation with routine use of extracorpo-
eal circulation, and post-operative hemodynamic instability
aused by RV or LV dysfunction after BLTx may result in
nferior early survival. However, 5- and 10-year survival
ates after BLTx for IPAH are similar to those seen with
ransplantation for other etiologies (58). Lung transplant
ecipients with IPAH who survived to 1 year had a
ignificantly better survival at 10 years than transplant
ecipients with chronic obstructive pulmonary disease and
diopathic pulmonary fibrosis.
Retrospective studies from individual centers showed
uperior early and long-term results after BLTx or com-
ined HLTx for IPAH (57,61). In a retrospective study
rom Pittsburgh (30 recipients who underwent transplanta-
ion between 1994 and 2006), actuarial survival was 86% at
year, 75% at 5 years, and 66% at 10 years (57). Early
eferral to a specialized multidisciplinary lung transplanta-
ion center familiar with the unique problems of PAH
atients and the complex transplantation procedure is key.
onsensus
Lung transplantation is the final effective treatment for
selected patients with IPAH.
The procedure of choice is BLTx or HLTx. Single-lung
procedures have been abandoned. Living lobar trans-
plants put donors at risk.
In choosing BLTx versus HLTx, organ donation rates,
local allocation protocols, and unit preference play a role.
Patients with PAH require 2 or 3 organs and may be
disadvantaged in some allocation systems.
ecommendations
Although drug therapy may delay transplantation, a class
IV patient who fulfills criteria should be referred for
transplantation assessment.Patients with veno-occlusive disease must be referred for
transplantation assessment at diagnosis.
Listing algorithms for transplantation in PAH must
incorporate hemodynamics because hemodynamics are
the primary determinant of survival, in addition to
functional class, exercise capacity, and failure to respond
to other therapies (Guidelines of the International Soci-
ety for Heart and Lung Transplantation define RAP
15 mm Hg, CO 2.0 l/min) (58).
xtracorporeal Support
xtracorporeal life support (ECLS) has been successfully
sed for cardiorespiratory support in neonates and children
62). Common indications for ECLS in adults are respira-
ory failure and acute respiratory distress syndrome (63).
ossible indications for ECLS in PAH are acute RV failure
nd hypoxemia caused by massive pulmonary embolism
63), bridge to lung transplantation, support after lung
ransplantation (64–66), and treatment of severe reperfu-
ion edema after PEA for CTEPH (67).
Extracorporeal life support is considered for patients with
H and potentially reversible right heart failure in whom
onventional support is failing, including optimized venti-
ation and fluid management, prone positioning, inhaled
itric oxide, prostanoid agents, and pharmacologic therapy
or right heart function (62).
The modes of ECLS are venovenous or venoarterial
ystems using the internal jugular or common femoral veins
nd/or common femoral, common carotid, or right axillary
rteries for cannulation (62,68). Venovenous ECLS is
seful for carbon dioxide removal, oxygenation, and RV
fterload reduction. Venoarterial ECLS is preferred for RV
ecompression and after lung transplantation (although
aving high mortality rates) because it provides more
ffective oxygenation.
Bleeding, neurological, infectious, and thromboembolic
omplications limit widespread use of ECLS (62,67). Con-
rolled randomized studies are not available and are unlikely
o be performed. However, ECLS can be a lifesaving option
n critically ill PAH patients and should be at hand in
pecialized PH centers.
Extracorporeal membrane oxygenation (ECMO) is a
aluable tool in lung transplantation, providing the potential
o bridge patients to transplantation, to replace cardiopul-
onary bypass with at least equal results, and to overcome
evere post-operative complications. Favorable survival rates
an be achieved despite the fact that ECMO is used in the
ore complex patient population undergoing lung trans-
lantation (69).
onclusions
When conventional support for the RV is ineffective,
ECLS may take several forms. Established modalities are:
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genation, RV afterload reduction
X venoarterial: preferred for RV decompression and sup-
port and after lung transplantation (although high mor-
tality if needed), providing more effective oxygenation
Devices include membrane oxygenators, centrifugal
pumps, and heparin-bonded systems.
onsensus
Extracorporeal life support can be lifesaving in critically
ill patients with RV failure, but no data are available from
randomized controlled trials.
Many questions remain regarding indications, timing,
and cannulation choice.
entricular Assist Devices
echanical circulatory support for the RV has been used for
atients refractory to medical therapy. The usual goal of
echanical circulatory support involving the RV is to bridge
he patients to lung transplantation.
Patients with end-stage right heart failure secondary to
PAH have fared poorly with pulsatile assist systems in
necdotal reports. The PAP typically increases markedly
ith pulsatile mechanical support because of the high
nergy imparted to blood by a pulsatile mechanical device,
ven with pumps that are pneumatically driven and set to
eliver the lowest possible dP/dT. The high dP/dT of
ulsatile ventricular assist devices results in damage to the
ulmonary microcirculation, with increased PVR and PAP
ften resulting in intraparenchymal pulmonary hemorrhage,
emoptysis, and death. The challenge is to increase flow
hrough a circulatory bed with inherently high resistance
nd high impedance attributable to derangements of
mooth muscle proliferation and vascular collagen accumu-
ation. Such patients may be best served by a support device
hat incorporates a gas exchange function in addition to a
irculatory function, taking blood from the venous circula-
ion and delivering it directly to the left atrium or arterial
irculation, thereby excluding the diseased RV and lungs
rom the patient’s circulatory system. Unfortunately,
CMO provides only short-term support in adults, and an
nflammatory response associated with the large prosthetic
urfaces of an oxygenator have limited its success.
Nonpulsatile flow axial or centrifugal flow devices—for
xample, roller pumps inserted percutaneously—may have
romise, with the potential for vascular remodeling, but
hey are largely untested.
onsensus
There is little literature on RV assist devices.
Right ventricular assist devices are effective in RV failure
secondary to LV failure.
Right ventricular assist devices with pulsatile flow cause
high distension pressure, and flow characteristics are less dadjustable than with nonpulsatile axial or centrifugal flow
devices.
In addition to short-term survival benefit, long-term
support may permit vascular remodeling.
There is a strong rationale for the development of such
devices.
ther Interventional Modalities
ovalung®. The Novalung® interventional Lung-Assist
iLA) membrane ventilator device (Novalung, GmbH, Ger-
any) is a pumpless extracorporeal lung-assist device used
n acute lung failure. It is driven by the patient’s CO and
oes not require extracorporeal pump assistance. A mem-
rane gas exchange system with optimized blood flow is
ntegrated in an arteriovenous bypass established by vascular
annulation. Novalung® has been applied in 4,000 patients
or artificial lung assistance with easy use and low cost (70).
tem cell transplantation. Circulating endothelial pro-
enitor cells instigate angiogenesis in PAH and home to the
ocation of endothelial damage, providing endothelial re-
air. Autologous endothelial progenitor cell transplantation
ay be explored in PAH in the future.
V synchronization. In PAH, significant interventricular
yssynchrony occurs because of a right bundle branch block
ith prolonged RV systolic contraction time, compared
ith the LV (71). This is probably caused by a decrease of
lectrical conductivity over the RV caused by high pre-
tretch of the RV myocardial fibers and the large force these
bers must generate to shorten. Dyssynchrony is known to
mpede LV diastolic filling (72).
In animal studies, opening the pericardium facilitates LV
lling, increases LV end-diastolic volume and output, and
educes septal bowing. Because a relationship exists between
ericardial pressure and RAP, and RAP is increased in
atients with severe PAH, diastolic interaction may theo-
etically be improved.
onsensus
Right ventricular resynchronization therapy has potential
and is likely to be safe enough for a pilot study in humans
with IPAH.
ovel shunts for PAH: Potts anastomosis or “de novo
uctus arteriosus,” a hypothetical exercise. The rationale
or creating new right-to-left shunts is that PAH patients
ith Eisenmenger physiology or patent foramen ovale
urvive longer than IPAH patients. Atrial septostomy is
ccepted as a mechanism for unloading the RV and
educing RV area, syncope, ascites, and edema. This
ccurs despite an 85% resting desaturation and a further
8% desaturation with exercise. A potential alternate
ecompression technique is to create a Potts anastomosis
side-to-side anastomosis from left pulmonary artery to
escending aorta) (73).
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June 30, 2009:S67–77 Interventional and Surgical Modalities of TreatmentSeven children with varying etiology (IPAH or corrected
ransposition) and suprasystemic PA pressure failing drug
herapy underwent Potts anastomosis (73). There was 1
echnical death. Follow-up at 26  22 months in the
emainder showed a tripling of 6MWD, improved func-
ional class, freedom from syncope, upper limb SaO2 97%,
ower limb 80%, and pulmonary artery and aortic pressures
qualized (74,75). In theory, this technique might be
pplicable in adults with IPAH, although some operative
isk is likely.
Purely hypothetical is the idea of creating a de novo
uctus arteriosus with conduit, which might perhaps be
alved to prevent aortic backpressure surges into the pul-
onary artery. Possible materials might be derived from LV
ssist device circuitry or arteriovenous fistulae formation for
ialysis, radial artery graft (used in coronary artery bypass
urgery), valved saphenous vein grafts, or new polymers.
onsensus. There is no consensus, given the paucity of
ata. The idea, however, is quite an exciting one, particu-
arly if it can be applied in adults in whom other therapies
ave failed.
uthor Disclosures
r. Keogh has received grant support from Bayer, Glaxo-
mithKline, Novartis, Pfizer, and Wyeth, and has served on
dvisory Boards for Actelion, Bayer, Encysive, Glaxo-
mithKline, Novartis, Pfizer, and Wyeth. Dr. Mayer has
eceived speaker and consulting fees from Actelion and
ayer Schering. Dr. Benza has received grant support from
ctelion, Gilead, Lung Rx, and United Therapeutics, and
peaking honoraria from Actelion, Gilead, and United
herapeutics. Dr. Corris has received research funding and
ees for advisory boards from Actelion, GlaxoSmithKline,
fizer, and Schering. Dr. Dartevelle reports no conflicts of
nterest. Dr. Frost has received research grants from Acte-
ion, Gilead, Eli Lilly, Pfizer, and United Therapeutics, and
onoraria for speaking and/or participation in speakers’
ureaus and advisory boards from Actelion, Gilead, Pfizer,
nd United Therapeutics. Dr. Kim has received speaker
onoraria from Actelion and Gilead and has served on a
teering committee for Bayer. Dr. Lang has received speaker
onoraria from Actelion and Gilead, and has served on a
teering committee for Bayer. Dr. Pepke-Zaba has received
peaker’s honoraria from Actelion, Bayer Schering, En-
ysive, and United Therapeutics and has served on an
dvisory board for Actelion. Dr. Sandoval has received
esearch grants from Actelion, Encysive, Gilead (Myogen),
fizer, and United Therapeutics, and consultant honoraria
rom Actelion, Encysive, and Bayer Schering.
eprint requests and correspondence: Prof. Anne M. Keogh, St.
incent’s Hospital, Victoria Street, Darlinghurst 2010, Sydney
SW, Australia. E-mail: amkeogh@stvincents.com.au.EFERENCES
1. Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic
thromboembolic pulmonary hypertension after pulmonary embolism.
N Engl J Med 2004;350:2257–64.
2. Lewczuk J, Piszko P, Jagas J, et al. Prognostic factors in medically
treated patients with chronic pulmonary embolism. Chest 2001;119:
818–23.
3. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thrombo-
embolic pulmonary hypertension. Circulation 2006;113;2011–20.
4. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in
patients with chronic major vessel thromboembolic pulmonary hyper-
tension. Chest 1993;103:685–92.
5. Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal
lesions and their cellular phenotypes in chronic pulmonary hyperten-
sion: a morphometric and immunohistochemical study. Am J Respir
Crit Care Med 2000;162:1577–86.
6. Auger WR, Kim NH, Kerr KM, Test VJ, Fedullo PF. Chronic
thromboembolic pulmonary hypertension. Clin Chest Med 2007;28:
255–69.
7. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic
pulmonary hypertension. Eur Respir J 2004;23:637–48.
8. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical
modalities of treatment for pulmonary arterial hypertension. J Am Coll
Cardiol 2004;43:73S–80S.
9. Ley S, Kauczor HU, Heussel CP, et al. Value of contrast-enhanced
MR angiography and helical CT angiography in chronic thromboem-
bolic pulmonary hypertension. Eur Radiol 2003;13:2365–71.
0. Coulden R. State-of-the-art imaging techniques in chronic thromboem-
bolic pulmonary hypertension. Proc Am Thorac Soc 2006;3:577–83.
1. Bresser P, Pepke-Zaba J, Jaïs X, Humbert M, Hoeper MM. Medical
therapies for chronic thromboembolic pulmonary hypertension: an
evolving treatment paradigm. Proc Am Thorac Soc 2006;3:594–600.
2. Hartz RS, Byrne JG, Levitsky S, Park J, Rich S. Predictors of mortality
in pulmonary thromboendarterectomy. Ann Thorac Surg 1996;62:
1255–9.
3. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary
endarterectomy: experience and lessons learned in 1,500 cases. Ann
Thorac Surg 2003;76:1457–64.
4. Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of
outcome in chronic thromboembolic pulmonary hypertension. Circu-
lation 2007;115:2153–8.
5. Kim NH. Assessment of operability in chronic thromboembolic
pulmonary hypertension. Proc Am Thorac Soc 2006;3:584–8.
6. Kim NH, Fesler P, Channick RN, et al. Preoperative partitioning of
pulmonary vascular resistance correlates with early outcome after
thromboendarterectomy for chronic thromboembolic pulmonary hy-
pertension. Circulation 2004;109:18–22.
7. Langer F, Bauer M, Tscholl D, et al. Circulating big endothelin-1: an
active role in pulmonary thromboendarterectomy? J Thorac Cardiovasc
Surg 2005;130:1342–7.
8. Suntharalingam J, Goldsmith K, Toshner M, et al. Role of NT-
proBNP and 6MWD in chronic thromboembolic pulmonary hyper-
tension. Respir Med 2007;101:2254–62.
9. Skoro-Sajer N, Mittermayer F, Panzenboeck A, et al. Asymmetric
dimethylarginine is increased in chronic thromboembolic pulmonary
hypertension. Am J Respir Crit Care Med 2007;176:1154–60.
0. Hardziyenka M, Reesink HJ, Bouma BJ, et al. A novel echocardio-
graphic predictor of in-hospital mortality and mid-term haemody-
namic improvement after pulmonary endarterectomy for chronic
thrombo-embolic pulmonary hypertension. Eur Heart J 2007;28:
842–9.
1. Condliffe R, Kiely D, Gibbs JS, et al. Prognostic and aetiological
factors in chronic thromboembolic pulmonary hypertension. Eur
Respir J 2009;33:332–8.
2. Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification
of thromboembolic disease determines outcome after pulmonary end-
arterectomy. J Thorac Cardiovasc Surg 2002;124:1203–11.
3. Hagl C, Khaladj N, Peters T, et al. Technical advances of pulmonary
thromboendarterectomy for chronic thromboembolic pulmonary hy-
pertension. Eur J Cardiothorac Surg 2003;23:776–81.
22
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
6
6
6
6
6
S76 Keogh et al. JACC Vol. 54, No. 1, Suppl S, 2009
Interventional and Surgical Modalities of Treatment June 30, 2009:S67–774. Thomson B, Tsui SS, Dunning J, et al. Pulmonary endarterectomy is
possible and effective without the use of complete circulatory arrest—
the UK experience in over 150 patients. Eur J Cardiothorac Surg
2008;33:157–63.
5. Mayer E, Klepetko W. Techniques and outcomes of pulmonary
endarterectomy for chronic thromboembolic pulmonary hypertension.
Proc Am Thorac Soc 2006;3:589–93.
6. Fedullo PF, Auger WR, Dembitsky WP. Postoperative management
of the patient undergoing pulmonary thromboendarterectomy. Semin
Thorac Cardiovasc Surg 1999;11:172–8.
7. Kramm T, Eberle B, Krummenauer F, Guth S, Oelert H, Mayer E.
Inhaled iloprost in patients with chronic thromboembolic pulmonary
hypertension: effects before and after pulmonary thromboendarterec-
tomy. Ann Thorac Surg 2003;76:711–8.
8. Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Tech-
niques and outcomes of pulmonary endarterectomy surgery. Ann
Thorac Cardiovasc Surg 2008;14:274–82.
9. D’Armini AM, Cattadori B, Monterosso C, et al. Pulmonary throm-
boendarterectomy in patients with chronic thromboembolic pulmo-
nary hypertension: hemodynamic characteristics and changes. Eur
J Cardiothorac Surg 2000;18:696–702.
0. Archibald CJ, Auger WR, Fedullo PF, et al. Long-term outcome after
pulmonary thromboendarterectomy. Am J Respir Crit Care Med
1999;160:523–8.
1. Condliffe R, Kiely D, Gibbs JS, et al. Improved outcomes in medically
and surgically treated chronic thromboembolic pulmonary hyperten-
sion. Am J Respir Crit Care Med 2008;15:1122–7.
2. Hughes R, Jaïs X, Bonderman D, et al. The efficacy of bosentan in
inoperable chronic thromboembolic pulmonary hypertension: a 1-year
follow-up study. Eur Respir J 2006;28:138–43.
3. Jaïs X, D’Armini AM, Jansa P, et al., for the BENEFiT Study Group.
Bosentan for treatment of inoperable chronic thromboembolic pulmo-
nary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms
of chronIc Thromboembolic pulmonary hypertension), a randomized,
placebo-controlled trial. J Am Coll Cardiol 2008;52:2127–34.
4. D’Alonso GE, Barst RJ, Ayres SM, et al. Survival in patients with
primary pulmonary hypertension: results from a national prospective
registry. Ann Intern Med 1991;115:343–9.
5. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison
of the hemodynamics and survival of adults with severe primary
pulmonary hypertension or Eisenmenger syndrome. J Heart Lung
Transplant 1996;15:100–5.
6. Hopkins WE. The remarkable right ventricle of patients with Eisen-
menger syndrome. Coron Artery Dis 2005;16:19–25.
7. Nihill MR, O’Laughlin MP, Mullins CE. Effects of atrial septostomy
in patients with terminal cor pulmonale due to pulmonary vascular
disease. Catheter Cardiovasc Diagn 1991;24:166–72.
8. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ.
Blade balloon atrial septostomy in patients with severe primary
pulmonary hypertension. Circulation 1995;91:2028–35.
9. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for
pulmonary hypertension with associated congenital heart defects.
Circulation 1999;99:1858–65.
0. Simonneau G, Barst RJ, Galiè N, et al., for the Treprostinil Study
Group. Continuous subcutaneous infusion of treprostinil, a prostacy-
clin analogue, in patients with pulmonary arterial hypertension: a
double-blind, randomized, placebo-controlled trial. Am J Respir Crit
Care Med 2002;165:800–4.
1. Galiè N, Beghetti M, Gatzoulis MA, et al., for the Bosentan Randomized
Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investiga-
tors. Bosentan therapy in patients with Eisenmenger syndrome: a
multicenter, double-blind, randomized, placebo-controlled study. Cir-
culation 2006;114:48–54.
2. Sandoval J, Gaspar J. Atrial septostomy. In: Peacock AJ, Rubin LJ,
editors. Pulmonary Circulation. 2nd Edition. London: Edward Ar-
nold, 2004:319–33.
3. Micheletti A, Hislop AA, Lammers A, et al. Role of atrial septostomy
in the treatment of children with pulmonary arterial hypertension.
Heart 2006;92:969–72.
4. Prieto LR, Latson LA, Jennings C. Atrial septostomy using a butterfly
stent in a patient with severe pulmonary arterial hypertension. Cath-
eter Cardiovasc Interv 2006;68:642–7.
5. Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary
hypertension. Clin Chest Med 2001;22:547–60.6. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial
septostomy in severe primary pulmonary hypertension: a therapeutic
alternative for patients nonresponsive to vasodilator treatment. J Am
Coll Cardiol 1998;32:297–304.
7. Vachiéry JL, Stoupel E, Boonstra A, Naeije R. Balloon atrial septos-
tomy for pulmonary hypertension in the prostacyclin era (abstr). Am J
Respir Crit Care Med 2003;167:A692.
8. Allcock RJ, O’Sullivan JJ, Corris PA. Atrial septostomy for pulmonary
arterial hypertension. Heart 2003;89:1344–7.
9. Rich S. Dodin E, McLaughlin VV. Usefulness of atrial septostomy as
a treatment for primary pulmonary hypertension and guidelines for its
application. Am J Cardiol 1997;80:369–71.
0. Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in
treatment of end-stage right heart failure in patients with pulmonary
hypertension. Chest 2007;131:977–83.
1. Ciarka A, Vachiéry JL, Houssière A, et al. Atrial septostomy decreases
sympathetic overactivity in pulmonary arterial hypertension. Chest
2007;131:1831–7.
2. Velez-Roa S, Ciarka A, Najem B, Vachiéry JL, Naeije R, van de Borne
P. Increased sympathetic nerve activity in pulmonary artery hyperten-
sion. Circulation 2004;110:1308–12.
3. Bristow MR, Zisman LS, Lowes BD, et al. The pressure-overloaded
right ventricle in pulmonary hypertension. Chest 1998;114:101S–6S.
4. Espı´nola-Zavaleta N, Vargas-Barro´n J, Tazar JI, et al. Echocardio-
graphic evaluation of patients with primary pulmonary hypertension
before and after atrial septostomy. Echocardiography 1999;16:625–34.
5. Doyle RL, McCrory D, Channick RN, Simonneau G, Conte J. Surgical
treatments/interventions for pulmonary arterial hypertension: ACCP
evidence-based clinical practice guidelines. Chest 2004;126:63S–71S.
6. Orens JB, Estenne M, Arcasoy S, et al., for the Pulmonary Scientific
Council of the International Society for Heart and Lung Transplan-
tation. International guidelines for the selection of lung transplant
candidates: 2006 update—a consensus report from the Pulmonary
Scientific Council of the International Society for Heart and Lung
Transplantation. J Heart Lung Transplant 2006;25:745–55.
7. Toyoda Y, Thacker J, Santos R, et al. Long-term outcome of lung and
heart-lung transplantation for idiopathic pulmonary arterial hyperten-
sion. Ann Thorac Surg 2008;86:1116–22.
8. Christie JD, Edwards LB, Aurora P, et al. Registry of the Interna-
tional Society for Heart and Lung Transplantation: twenty-fifth
official adult lung and heart/lung transplantation report—2008.
J Heart Lung Transplant 2008;27:957–69.
9. Kawut SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel
SE. Hemodynamics and survival in patients with pulmonary arterial
hypertension related to systemic sclerosis. Chest 2003;123:344–50.
0. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH.
Heart-lung or lung transplantation for Eisenmenger syndrome.
J Heart Lung Transplant 2002;21:731–7.
1. de Perrot M, Chaparro C, McRae K, et al. Twenty-year experience of
lung transplantation at a single center: influence of recipient diagnosis
on long-term survival. J Thorac Cardiovasc Surg 2004;127:1493–501.
2. Conrad SA, Rycus PT, Dalton H. Extracorporeal Life Support
Registry Report 2004. ASAIO J 2005;51:4–10.
3. Maggio P, Hemmila M, Haft J, Bartlett R. Extracorporeal life support
for massive pulmonary embolism. J Trauma 2007;62:570–6.
4. Vlasselaers D, Verleden GM, Meyns B, et al. Femoral venoarterial
extracorporeal membrane oxygenation for severe reimplantation re-
sponse after lung transplantation. Chest 2000;118:559–61.
5. Fischer S, Bohn D, Rycus P, et al. Extracorporeal membrane oxygen-
ation for primary graft dysfunction after lung transplantation: analysis
of the Extracorporeal Life Support Organization (ELSO) registry.
J Heart Lung Transplant 2007;26:472–7.
6. Pereszlenyi A, Lang G, Steltzer H, et al. Bilateral lung transplantation
with intra- and postoperatively prolonged ECMO support in patients
with pulmonary hypertension. Eur J Cardiothorac Surg 2002;21:858–63.
7. Thistlethwaite PA, Madani MM, Kemp AD, Hartley M, Auger WR,
Jamieson SW. Venovenous extracorporeal life support after pulmonary
endarterectomy: indications, techniques, and outcomes. Ann Thorac
Surg 2006;82:2139–45.
8. Kahn J, Müller H, Marte W, et al. Establishing extracorporeal
membrane oxygenation in a university clinic: case series. J Cardiotho-
rac Vasc Anesth 2007;21:384–7.
67
7
7
7
7
7
K
S77JACC Vol. 54, No. 1, Suppl S, 2009 Keogh et al.
June 30, 2009:S67–77 Interventional and Surgical Modalities of Treatment9. Aigner C, Wisser W, Taghavi S, et al. Institutional experience with
extracorporeal membrane oxygenation in lung transplantation. Eur
J Cardiothorac Surg 2007;31:468–74.
0. Walles T. Clinical experience with the iLA Membrane Ventilator
pumpless extracorporeal lung-assist device. Expert Rev Med Devices
2007;4:297–305.
1. Gan CT, Lankhaar JW, Marcus JT, et al. Impaired left ventricular
filling due to right-to-left ventricular interaction in patients with
pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol
2006;290:H1528–33.
2. Tyberg JV, Taichman GC, Smith ER, Douglas NW, Smiseth OA,
Keon WJ. The relationship between pericardial pressure and right
atrial pressure: an intraoperative study. Circulation 1986;73:428–32. m3. Zipes D, Libby P, Bonow R, Braunwald E, editors. In: Braunwald’s
Heart Disease: A Textbook of Cardiovascular Medicine. 5th edition.
Philadelphia, PA: WB Saunders, 2005.
4. Blanc J, Vouhé P, Bonnet D. Potts shunt in patients with pulmonary
hypertension (letter). N Engl J Med 2004;350:623.
5. Serraf A, Petit J, Belli E, et al. Potts anastomosis for severe pulmonary
arterial hypertension in children. Presented at: American Thoracic
Society International Conference; May 2007; San Diego, CA.
ey Words: surgical modalities y treatment in PAH y interventional
odalities.
